BOLT Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system...

Stats
Объем за сегодня	122 267
Средний объем	132 000
Рыночная капитализация	42.32M
EPS	$0 ( 2024-04-03 )
Дата следующего отчета о доходах	( $-0.510 ) 2024-05-09
Last Dividend	$0.0900 ( 2014-08-29 )
Next Dividend	$0 ( N/A )
P/E	-0.610
ATR14	$0.0170 (1.53%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Yonehiro Grant	Buy	235 000	Stock Option (Right to Buy)
2024-03-04	Perez Edith A.	Buy	235 000	Stock Option (Right to Buy)
2024-03-04	Schatzman Randall C	Buy	654 000	Stock Option (Right to Buy)
2024-03-04	Quinn William P.	Buy	235 000	Stock Option (Right to Buy)
2023-12-31	Yonehiro Grant	Buy	0

INSIDER POWER
72.63
Last 93 transactions
Buy: 5 349 325 \| Sell: 1 125 168

Объем Корреляция

Длинно: -0.10 (neutral)

Кратко: -0.58 (weak negative)

Signal:(42.788) Neutral

Bolt Biotherapeutics, Корреляция

10 Самые положительные корреляции

10 Самые отрицательные корреляции
SITM	-0.817
IRBT	-0.81

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Bolt Biotherapeutics, Корреляция - Валюта/Сырье

-0.42
( neutral )

-0.27
( neutral )

0.00
( neutral )

0.07
( neutral )

0.54
( weak )

Bolt Biotherapeutics, Финансовые показатели

Annual	2023
Выручка:	$7.88M
Валовая прибыль:	$5.99M (76.08 %)
EPS:	$-1.830

FY	2023
Выручка:	$7.88M
Валовая прибыль:	$5.99M (76.08 %)
EPS:	$-1.830

FY	2022
Выручка:	$5.73M
Валовая прибыль:	$838 000 (14.63 %)
EPS:	$-2.30

FY	2021
Выручка:	$0.00
Валовая прибыль:	$0.00 (0.00 %)
EPS:	$-2.97

Financial Reports:

No articles found.

Bolt Biotherapeutics, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bolt Biotherapeutics, Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0.326 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0500	2012-03-06
Last Dividend	$0.0900	2014-08-29
Next Dividend	$0	N/A
Payout Date	2014-10-02
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$0.830	--
Avg. Dividend % Per Year	0.00%	--
Score	1.61	--
Div. Sustainability Score	0.326
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-18)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

1.61

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-8.60	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.424	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.501	1.500	-6.68	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	5.16	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.06	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.528	1.500	8.18	10.00	[0.2 - 2]
debtRatioTTM	0.127	-1.500	7.89	-10.00	[0 - 0.6]
interestCoverageTTM	53.10	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.832	2.00	-0.611	-1.222	[0 - 30]
freeCashFlowPerShareTTM	-1.838	2.00	-0.919	-1.838	[0 - 20]
debtEquityRatioTTM	0.179	-1.500	9.28	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.577	1.000	3.72	3.72	[0.2 - 0.8]
operatingProfitMarginTTM	-9.67	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-3.44	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0493	0.800	-3.00	-2.40	[0.5 - 2]
Total Score				0.326

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.622	1.000	-0.164	0	[1 - 100]
returnOnEquityTTM	-0.501	2.50	-4.29	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.838	2.00	-0.613	-1.838	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.832	2.00	-0.611	-1.222	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00463	1.500	-3.30	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-8.83	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.76

Bolt Biotherapeutics,

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.